Source comparison
ARA-290 Side Effects: Clinical Trial vs Real-World Comparison
Below is a structured comparison of adverse event reporting across controlled trial settings versus observational research applications, with professional assessment of the pattern differences and their implications for protocol design. Injection site reaction
This comparison does not assign a generated winner or score.
- Below is a structured comparison of adverse event reporting across controlled trial settings versus observational research applications, with professional assessment of the pattern differences and their implications for protocol design.
- Injection site reaction
- 8–12% (mild erythema/induration, self-resolving within 48 hours)
- 15–20% (likely reflects variable injection technique and reconstitution practices outside protocol standardization)
- Higher real-world incidence suggests technique training reduces this effect. Proper rotation, temperature equilibration, and slow injection matter
- Transient headache
- 6–9% (mild to moderate, tension-type, responsive to standard analgesics)
- 5–8% (similar presentation and severity profile)
- No meaningful difference. Suggests headache incidence is pharmacologically mediated rather than protocol-related
- Fatigue
- 5% (typically first week, self-resolving by day 14–21)
- 8–11% (reported more frequently, may persist longer in some cases)
- Real-world increase may reflect less stringent inclusion criteria. Subjects with baseline metabolic dysfunction or concurrent medications not excluded
- Laboratory abnormalities
- 0% clinically significant changes in CBC, CMP, LFTs through 28 days
- <2% transient AST/ALT elevation (1.2–1.8× ULN, reversible, causality unclear)
- Controlled trials exclude subjects with hepatic impairment. Real-world application includes broader populations where unrelated transient enzyme changes occur
- Serious adverse events
- <5% (none causally attributed to ARA-290 in any published trial)
- Similar rate, no clear causal pattern emerging
- Safety profile remains consistent across settings. SAEs reflect underlying disease burden rather than treatment effect